Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar i disorder

Journal of Medical Economics

Volumn 12, Issue 4, 2009, Pages 259-268

  Woodward, Tatia Chay ^a   Tafesse, Eskinder ^b   Quon, Peter ^a   Kim, Jennifer ^b   Lazarus, Arthur ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bipolar I disorder; Cost effectiveness; Maintenance treatment; Quetiapine

Indexed keywords

LAMOTRIGINE; LITHIUM; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH STATUS; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICIAN; POLYPHARMACY; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MARKOV CHAINS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VALPROIC ACID; YOUNG ADULT;

EID: 72749092639     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903266612     Document Type: Article

References (32)

1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF 36. J Health Econ 2002;21:271-292.
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552.
3. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003;21:601-622.
4. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994;31:91-96.
5. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008;20:131-137.
6. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-808; quiz 809.
7. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-219.
8. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495.
9. Knoth RL, Chen K, Tafesse E. Datapoints: costs associated with the treatment of patients with bipolar disorder in a managed care organization. Psychiatr Serv 2004;55:1353.
10. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50.
11. McIntyre RS, Woldeyohannes HO, Yasgur BS, et al. Maintenance treatment in bipolar disorder: a focus on aripiprazole. Expert Rev Neurother 2007;7:919-925.
12. Astrazeneca. Seroquel - Prescribing Information, 2007.
13. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-263.
14. Suppes T, Liu S, Brecher M, Paulsson B, on behalf of the Trial 127 Investigators. Maintenance treatment in bipolar I disorder with quetiapine with lithium or divalproex: a placebo-controlled, randomized multicenter trial (trial D1447C00127). Bipolar Disord 2008;10(Suppl 1):40.
15. Lipscomb J, Weinstein M, Torrance GW. Time preference. In: Gold MR, Siegel J, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996;214-246.
16. Simon GE, Hunkeler E, Fireman B, et al. Risk of suicide attempt and suicide death in patients treated for bipolar disorder. Bipolar Disord 2007;9:526-530.
17. NCHS. National Vital Statistics Report. Deaths: Final Data for 2004.
18. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6.
19. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024. (Pubitemid 37158246)
20. Calvert NW, Burch SP, Fu AZ, et al. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 2006;12:322-330.
21. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400. (Pubitemid 36403000)
22. Thomson P. Red Book [TM] for Windows (2007) Vol 43.
23. US Department of Labor BoLS. Consumer price indexes: US Depart. of Labor, Bureau of Labor Statistics [on-line]. Available at: http://www.bls.gov/cpi/ [Last accessed 10 Oct 2007].
24. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481.
25. Briggs A, Gray A. Using cost-effectiveness information. BMJ 2000;320:246.
26. Soares-Weiser K, Bravo Vergel, Y Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:iii-iv
27. Fleurence RL, Chatterton ML, Dixon JM, Rajagopalan K. Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review. Prim Care Companion J Clin Psychiatry 2007;9:419-428.
28. Kessing LV, Munk-Jorgensen P. Does type of first contact in depressive and bipolar disorders predict subsequent hospitalisation and risk of suicide? J Affect Disord 2004;83:65-71.
29. DeFrances CJ, Cullen KA, Kozak LJ. National hospital discharge survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13, 2007:Table 13.
30. Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005;23:583-594.
31. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48:25-36.
32. McKendrick J, Cerri KH, Lloyd A, et al. Cost-effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 2007;21:588-596.